AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 17 - (NewsRx.com & NewsRx.net) -- Marshall Edwards, Inc., (MSH), the subsidiary of pharmaceutical company, Novogen Limited (NVGN), has entered into a services agreement with the Yale University School of Medicine's Department of Obstetrics and Gynecology.
The association with Yale revolves around the recent discovery in Yale Medical School laboratories that MEI's anticancer drug, phenoxodiol, has a uniquely strong effect against ovarian cancer cells.
Ovarian cancer is the fifth largest cause of death from cancer in women, and the American Cancer Society estimates that over 23,000 women will develop ovarian cancer in the U.S. each year. The treatment options and prognosis for women with late-stage ovarian cancer remain poor.
In a search for an effective drug to treat ovarian cancer, the research team at Yale University Medical School, headed by Gil Mor, MD, PhD, has been screening new anticancer drugs for their ability to kill ovarian ...
Source: HighBeam Research, Yale researchers reveal Phenoxodiol's unique ability to kill cancer...